引述本篇研究內容:「The main outcome was that only the highest dose of myo-inositol (12 g/day) induced mild gastrointestinal side effects such as nausea, flatus and diarrhea. The severity of side effects did not increase with the dosage.」
3. Inositol and Antioxidant Supplementation : Safety and Efficacy in Pregnancy. Diabetes Metab Res Rev. 2019 Jul; 35(5): e3154.
在這篇研究中,標題就開宗明義地指出本篇是探討懷孕期間補充肌醇和其他抗氧化劑的安全性與效果。
引述研究內容:「In clinical trials in which inositol dosages ranged from 4 to 60 g/day and the exposure time ranged from 1 to 12 months, the only adverse events reported were mild gastrointestinal symptoms (nausea, flatus, and diarrhoea) but only at doses greater of 12 g per day.」
引述本篇研究內容:「According to the aforementioned data, inositol is defined as generally recognized as safe (GRAS) by the FDA, which allows its use also in infants. 」
而根據前述資料與研究,美國 FDA 將肌醇訂為安全食品成分認證 GRAS (Generally Recognize as Safe) 成分,代表即使嬰幼兒也可以食用。
4. Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2019 Jan;299(1):55-68.
引述本篇研究結論:「 Inositol (ISLs) administration during pregnancy appears to be safe and may represent a novel strategy for GDM prevention. In particular, the double administration of MYO 2 g per day may improve the glycemic homeostasis and may reduce GDM rate and preterm delivery rate. 」